Strategic partnerships within the biopharmaceutical industry are key to accelerating the process of getting medicines to patients. I recently sat down with Pallavi Garg, Head of the U.S. Oncology Business Unit at Takeda, to explore how collaboration in our industry is driving progress in the fight against cancer.
Our discussion highlights how Takeda’s partnerships are not just addressing unmet needs in oncology, but also breaking down barriers to innovation. These efforts align with our industry’s goal: ensuring groundbreaking medicines reach patients when they need them most.
Watch the video to learn more about Takeda’s patient-centric approach to shaping the future of oncology research.
Since recording this video, Pallavi’s role has shifted to Head of the U.S. Oncology Business Unit at Takeda.
Lori M. Reilly, Esq.
Lori M. Reilly is chief operating officer at PhRMA, providing executive level management, leadership and strategic direction for the organization. In this role, Reilly oversees PhRMA’s advocacy activities, including its federal, state and international government affairs and alliance development work. Reilly provides strategic leadership and works across PhRMA to develop and advocate for practical policy solutions that will lower costs for patients.
Reilly, named by the Washingtonian as one of the 250 most influential people in D.C., has a long record of working with members of Congress on a bipartisan basis and collaborating with stakeholders across the health care industry. Reilly is a frequent presenter on industry-related issues, including testifying before Congress on multiple occasions.
Reilly has over two decades of experience at PhRMA; prior to her current role, Reilly was the executive vice president of policy, research and membership at PhRMA, leading the development and implementation of legislative, regulatory and political strategies to advance policies that encourage patient access and medical innovation. She has also served as counsel at the U.S. House of Representatives Committee on Commerce and was Counsel to a member of the House Ways and Means Committee.
Reilly received a B.A. in political science from the University of Nebraska-Lincoln where she graduated with honors, and a J.D. from the University of Nebraska College of Law. She currently resides in Alexandria, Virginia with her husband and their four children.
Lori Reilly
https://www.linkedin.com/in/lorireillyphrma/
Chief Operating Officer
New study: HPV vaccination helps prevent cervical cancer deaths
Staffing up: Building the future biopharma workforce to keep America in the lead
Nearly 80 researchers advocate on Capitol Hill
America's cancer research progress is real and worth protecting
Ahead of ASCO: Cancer innovation is promising, but policy choices matter
Advancing patient care: A look at new medicines approved in 2025
Congratulations to our 2026 Working for Cures Employee Champions
CAREs 2025: Supporting community-based solutions that improve access to medicines
New analysis finds 340B hospitals push patients toward costly care to boost profits
Price setting policies put cancer gains in jeopardy
Manufacturing U.S. jobs and breakthroughs
Historic biopharmaceutical investments: A prescription for America’s future
Bringing to life the full story of biopharmaceutical innovation and investments
From sound to science: How IP powers innovation in music and hearing
Improved treatments continue to lead to declining cancer mortality rates in the U.S.
Guest Perspective: Prioritize Innovative Care
Preventing and fighting disease: A look at the biopharmaceutical progress made for patients in 2024
Recognizing the value of disease prevention with Dr. Len Friedland from GSK
Congratulations to our 2024 Working for Cures Employee Champions
Post-approval R&D is critical for fighting cancer. The IRA makes it more difficult.
New research: American biopharmaceutical investment in R&D drives transformational innovation
The future of oncology R&D lies in policymakers’ hands
More than 60 researchers advocate on Capitol Hill
Showcasing the promise of biopharma at ASCO 2024
Alzheimer's & Brain Awareness Month: A conversation with Biogen
Alzheimer's & Brain Awareness Month: A conversation with Eisai
Alzheimer's & Brain Awareness Month: A conversation with Eli Lilly and Company
Championing cancer equity: Our drive for healthier AANHPI communities
The impact of innovative medicines: A caregiver's perspective
PhRMA awards $250,000 to community-based projects to improve equitable cancer outcomes
Three things to know about antibody drug conjugates
Powering the next generation of therapies: A conversation with Astellas US President Mark Reisenauer
Congratulations to our 2023 Working for Cures Employee Champions
Watch: Putting patients front and center for World AIDS Day
The IRA’s pill penalty threatens the future of oncology R&D
New Report: 1,600 cancer treatments and vaccines in clinical development
R&D leaders to Biden Administration: Your policies are undermining the Cancer Moonshot
Watch: New video series spotlights advances in biopharmaceutical science
Between hope and despair: Improving cancer outcomes
New report shows high-impact R&D happens after cancer medicines are first approved
More than 60 researchers ask Congress to support innovation
New report shows how the Inflation Reduction Act stifles innovation for small molecule medicines
Biopharmaceutical science powered by PRIDE
ASCO 2023: Protecting our progress in the fight against cancer
Highlights from ASCO 2023
Addressing Mental Health: A conversation with Barry Greene, CEO of Sage Therapeutics
World IP Day 2023: Celebrating women leaders in innovation
IRA Impacts: Cancer treatment research and development
What we’ve learned from three years of fighting COVID-19
State policymakers can protect American innovation and help Americans live longer, healthier lives
ICYMI: Cancer death rate continues to decline due to treatment advances
Novel medicines approved in 2022 offer increased treatment options for patients
WTAS: Inflation Reduction Act already impacting R&D decisions
Sparking conversations — and careers — at the 2nd annual Pathways to Success Summit
Stories from the lab: Researchers discuss innovative treatments for cancers of the blood
Congratulations to our 2022 Working for Cures Employee Champions
ICYMI: PhRMA COO Lori Reilly Esq. speaks with Jacob Van Naarden about the future of cancer research
Protecting treatment advances for breast cancer
Protecting against influenza: A conversation with David Ross, Vice President, Commercial Operations, North America, CSL Seqirus
An open letter to Congress: Stand with patients and future cures
PhRMA member companies’ R&D investments reach record high of $102.3 billion in 2021
Key takeaways from ASCO's annual meeting
Biopharmaceutical researchers to discuss the value of R&D with Congress
ICYMI: First pediatric patient to receive CAR-T cell therapy celebrates 10 years of being cancer-free
Report: More than 500 medicines in development to treat disorders of the blood
A conversation with Barry Greene, CEO of Sage Therapeutics
Stephanie Dyson of BMS on reducing health disparities
Biopharmaceutical industry drives economic growth in all 50 states
4 things to know about biopharmaceutical efforts to fight cancer
Guest post: Joining forces to combat the COVID-19 mental health crisis
New data show continued decline in death rates for cancer patients related to treatment advances
Upcoming graduate student summit will showcase pathways to success within the biopharmaceutical industry
Guest Series: PhRMA talks racial and health equity with Lauren Powell, VP US Health Equity and Community Wellness, Takeda
Industry leaders discuss the impact of the drug pricing debate
Recognizing National Immunization Awareness Month
PhRMA member companies’ R&D investments reach record high of $91.1 billion in 2020
Watch: Building trust and enhancing clinical trial diversity
Building a better health care system: A conversation with Mark Reisenauer, President of Astellas US
Researchers to shine light on biopharmaceutical R&D with policymakers
Key takeaways: PhRMA comments to USPTO on how to make the innovation ecosystem more diverse and inclusive
Coming together to fight COVID-19: A conversation with Paul Perreault, CEO and Managing Director of CSL
Action needed to preserve the six protected classes
Guest post: PhRMA talks racial and health equity with Stephanie Dyson, Head of Office at Biogen
ICYMI: Cancer death rate continues decline due to advances in treatment
Report highlights biopharmaceutical industry’s commitment to D&I
Report: More than 1,300 medicines and vaccines in development to help fight cancer
Guest Post: Bringing our best to the fight against COVID-19
An unprecedented year and the road ahead: A conversation with Giovanni Caforio, PhRMA Chairman and CEO of Bristol Myers Squibb
Coming together to fight COVID-19: A conversation with Peter Anastasiou, Executive Vice President of Lundbeck
Study finds biopharmaceutical innovation is responsible for 35% of the increase in life expectancy from 1990 to 2015
New Report: The biopharmaceutical industry’s sustained commitment to inspiring and advancing tomorrow’s STEM workforce
Coming together to fight COVID-19: A conversation with Alexander Hardy, CEO of Genentech
Leading researchers to spotlight the critical role of biopharmaceutical R&D
Coming together to fight COVID-19: A conversation with Ramona Sequeira, President of Takeda Pharmaceuticals U.S.A
Coming together to fight COVID-19: A conversation with Albert Bourla, Chairman & CEO of Pfizer, Inc.
Guest Post: How proactivity and planning helped Novartis ensure a stable supply of medicines during COVID-19
PhRMA member companies invested $83 billion in research and development last year
Coming together to fight COVID-19: A conversation with Paul Hudson, CEO of Sanofi
Three ways the pharmaceutical industry can positively impact health equity
ICYMI: The latest as America’s biopharmaceutical companies work to beat COVID-19
New report explores setbacks that bring future cancer success stories
In combating COVID-19, science is how we get back to normal
Guest Post: Takeda seeks ‘new normal’ for cancer research during the COVID-19 pandemic
Guest Post: What will we learn from COVID-19?
Lilly, Merck and Pfizer empower team members to volunteer on COVID-19 frontlines
To the millions affected by COVID-19
Merck’s Dr. Julie Gerberding on the threat of antimicrobial resistance and COVID-19
The biopharmaceutical industry’s unique role in responding to COVID-19
ICYMI: America’s biopharmaceutical companies are working 'around the clock' to beat coronavirus
COVID-19 Response: Supporting the frontline
Guest post: Looking out for the invisibly vulnerable in the time of COVID-19
America’s biopharmaceutical companies are working around the clock to beat coronavirus
Guest post: Takeda’s efforts to address COVID-19
ICYMI: America’s biopharmaceutical companies are taking on COVID-19
ICYMI: Continued biopharmaceutical action on COVID-19
Working together to combat coronavirus
Cancer medicines cost twice as much at hospitals, study finds
Saving kids and dogs from shared cancers
New analysis shows that more medicines worldwide are available to U.S. patients
New analysis shows that HTA organizations may frequently restrict access to cancer treatments
New report and resources put cancer in context, showing more than 1,100 medicines and vaccines in development
Spending on medicines grew less than one percent in 2017
Patients pay the price when hospitals mark up cancer medicines
A new era in cancer
PhRMA, member companies and NIH create public-private partnership for immuno-oncology
The journey to better health care requires a holistic view
What they are saying: Study on cancer R&D costs is not an accurate representation of marketplace
Protect your health: Important disaster preparedness tips for Harvey and Irma
Helping those affected by the 2017 hurricane season
Medicare Monday: New report highlights progress in fighting cancer with new physician-administered medicines
Celebrating PRIDE in biopharmaceutical science
More than 240 immuno-oncology treatments in development to fight cancer
Medicines have significantly increased chances of cancer survival around the globe
ICYMI: Report highlights overall decrease in cancer death rates
Guest Post: The importance of a modern FDA in drug discovery
Exploring the new era of medicine
Guest Post: Johnson and Johnson is celebrating outstanding scientists: Who will be next?
Watch: Biomarkers in drug development with Dr. Bernie Zeiher
This is not a video game: New TV ad showcases the destruction of a cancer cell by immune system
The 20-year journey yielding a new weapon against cancer
Significant progress fighting cancer: Death rate has dropped 25 percent
The importance of partnership: A conversation with Takeda
Cancer
PhRMA Member Company
The importance of partnership: A conversation with Takeda
The importance of partnership: A conversation with Takeda